Sort By Category

All
Investor Presentations
Interviews
Investor News
Company News

Latest News

Company Name Change

Change of company name from Admedus to Anteris Technologies

26th May 2020

Investor Presentation

Creating the World's Most Durable Heart Valve

21st May 2020

Admedus AGM 2020

Admedus 2020 AGM CEO Presentation

15th May 2020

Admedus 2020 AGM

Admedus 2020 AGM Video

14th May 2020

CEO Wayne Paterson is interviewed by Proactive Investors

CEO Wayne Paterson is interviewed by proactive investors to provide an update on Admedus in light of COVID-19

6th Apr 2020

First patient implanted with DurAVR™

Admedus implants first patient with their 3D single piece aortic valve

31st Mar 2020

Admedus is proud to announce the successful implantation of its ADAPT® treated single piece 3D aortic valve.

Admedus Limited announces the first implantation of its ADAPT® treated 3D single piece aortic valve in a patient with aortic stenosis.

29th Mar 2020

Investor Q&A with Dr. Paul Sorajja & our CEO

Dr. Paul Sorajja shares his view on Admedus' TAVR

20th Mar 2020

Credit Suisse Equity Research – US Medical Supplies & Devices

Week of Pre-Releases and Meetings Point to Solid Fundamentals and Healthy Innovation See the report here

1st Feb 2020

First-In-Human SAVR Trial Begins Q1 2020

ANNOUNCEMENT First-In-Human SAVR Trial Begins Q1 2020. Admedus Limited announces approval for first-in-human surgical aortic valve replacement (SAVR) trial of its proprietary ADAPT® single-piece 3D aortic valve at the Leuven University Hospitals.

23rd Jan 2020

CEO Wayne Paterson discusses the opportunities in the TAVR market

Since taking the helm of Admedus Ltd. in 2017, CEO, Wayne Paterson has steered the ASX small-cap company into a real contender for disrupting the global transcatheter aortic valve replacement (TAVR) market. Its innovative ADAPT® technology not only slashes surgical…

6th Jan 2020

ADAPT tissue is “going to be a game-changer”

Michael Reardon (Houston, USA) talks to BLearning Cardio about the ADAPT tissue technology (Admedus), and the increasing importance of durability as TAVI moves to younger and lower risk patients. Reardon notes that “we would like to have technology that does…

27th Nov 2019